Novo Nordisk A/S: Ryzodeg(R) (insulin degludec/insulin aspart)

Novo Nordisk A/S: Ryzodeg(R) (insulin degludec/insulin aspart) passed
the review by the First Committee on Drugs of Pharmaceutical Affairs
in Japan 
BAGSVAERD, DENMARK -- (Marketwire) -- 12/03/12 --   Novo Nordisk
today announced that Ryzodeg(R) (insulin degludec/insulin aspart) has
passed the review by the First Committee on Drugs of Japan's
Pharmaceutical Affairs. The remaining step in the regulatory process
is an approval from the Ministry of Health, Labour and Welfare. 
Company announcement No 78 / 2012:
http://hugin.info/2013/R/1661613/538373.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein. 
Source: Novo Nordisk A/S via Thomson Reuters ONE 
[HUG#1661613] 
Further information Media:
Mike Rulis
+45 4442 3573
mike@novonordisk.com 
Ambre Morley (US)
+1 609 216 5240
abmo@novonordisk.com 
Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
krop@novonordisk.com 
Frank Daniel Mersebach
+45 4442 0604
fdni@novonordisk.com 
Lars Borup Jacobsen
+45 3075 3479
lbpj@novonordisk.com 
Jannick Lindegaard (US)
+1 609 786 4575
jlis@novonordisk.com